Page last updated: 2024-09-04

canertinib and Neutropenia

canertinib has been researched along with Neutropenia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arun, BK; Eder, JP; Eiseman, IA; Garland, LL; Hidalgo, M; Lenehan, PF; Lovalvo, JL; Mendelson, DS; Olson, SC; Ryan, DP	1
Bitran, JD; Burnett, D; Chiappori, AA; Eiseman, I; Ellis, PM; Hamm, JT; Lenehan, P; Lovalvo, J; Olson, S; Zinner, RG	1

Trials

2 trial(s) available for canertinib and Neutropenia

Article	Year
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-15, Volume: 12, Issue:14 Pt 1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Chemical; Morpholines; Neoplasms; Neutropenia; Taxoids	2006
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Odds Ratio; Paclitaxel; Patient Selection; Probability; Prognosis; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; United States	2006

Article

Year

A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-15, Volume: 12, Issue:14 Pt 1

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Chemical; Morpholines; Neoplasms; Neutropenia; Taxoids

2006

A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9

Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Odds Ratio; Paclitaxel; Patient Selection; Probability; Prognosis; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; United States

2006